Glenmark Pharmaceuticals’ arm gets tentative approval for Axitinib Tablets

01 Dec 2020 Evaluate

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Inc., USA, has received tentative approval by the United States Food & Drug Administration (USFDA) for Axitinib Tablets, 1mg and 5 mg, the generic version of Inlyta Tablets, 1 mg and 5 mg, of PF Prism C.V. Sales data for the 12 month period ending October 2020, the Inlyta Tablets, 1 mg and 5 mg market achieved annual sales of approximately $518.8 million.

The company’s current portfolio consists of 166 products authorized for distribution in the U.S. marketplace and 45 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. 

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1021.15 15.00 (1.49%)
17-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1530.00
Dr. Reddys Lab 5802.00
Cipla 1399.35
Zydus Lifesciences 1051.90
Lupin 1653.75
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.